Relapsing Remitting Multiple Sclerosis News and Research

RSS
FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Elan's first-quarter total revenue up by 27% to $310.5M

Elan's first-quarter total revenue up by 27% to $310.5M

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Copaxone achieves one million patient years of experience in treatment of RRMS

Copaxone achieves one million patient years of experience in treatment of RRMS

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

New study shows utility of Chronix Biomedical's serum DNA tests in MS

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

UAB researchers discover first bio-marker for MS

UAB researchers discover first bio-marker for MS

Biogen Idec and Elan begin comparative trial of MS treatments

Biogen Idec and Elan begin comparative trial of MS treatments

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

EMD Serono announces results from CLARITY Phase III trial in MS patients

EMD Serono announces results from CLARITY Phase III trial in MS patients

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA